Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells

One mechanism of resistance of prostate cancer (PCa) to enzalutamide (MDV3100) treatment is the increased expression of AR variants lacking the ligand binding-domain, the best characterized of which is AR-V7. We have previously reported that Phosphatidylinositol-4-phosphate 5-kinase alpha (PIP5Kα),...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Sarwar, Martuza, Semenas, Julius, Miftakhova, Regina, Simoulis, Athanasios, Robinson, Brian, Wingren, Anette Gjörloff, Mongan, Nigel P., Heery, David M., Johnsson, Heather, Abrahamsson, Per-Anders, Dizeyi, Nishtman, Luo, Jun, Persson, Jenny L.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5325347/
https://ncbi.nlm.nih.gov/pubmed/27588408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11757
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados